BCAB Key Statistics, Chart & Performance
The current stock price of BCAB is 0.904 USD. In the past month the price increased by 30.11%. In the past year, price decreased by -46.19%.
BCAB Latest News, Press Relases and Analysis
BCAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About BCAB
Company Profile
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121 US
CEO: Jay M. Short
Employees: 61
Phone: 18585580708
BIOATLA INC / BCAB FAQ
What does BIOATLA INC do?
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
What is the stock price of BIOATLA INC today?
The current stock price of BCAB is 0.904 USD. The price increased by 6.27% in the last trading session.
What is the dividend status of BIOATLA INC?
BCAB does not pay a dividend.
How is the ChartMill rating for BIOATLA INC?
BCAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about BIOATLA INC (BCAB) stock?
9 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 1028.32% is expected in the next year compared to the current price of 0.904.
What is the GICS sector and industry of BCAB stock?
BIOATLA INC (BCAB) operates in the Health Care sector and the Biotechnology industry.
What is BIOATLA INC worth?
BIOATLA INC (BCAB) has a market capitalization of 53.15M USD. This makes BCAB a Micro Cap stock.
BCAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BCAB. When comparing the yearly performance of all stocks, BCAB is one of the better performing stocks in the market, outperforming 87.73% of all stocks.
BCAB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCAB. The financial health of BCAB is average, but there are quite some concerns on its profitability.
BCAB Financial Highlights
Over the last trailing twelve months BCAB reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 32.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.1% | ||
| ROE | -489.14% | ||
| Debt/Equity | 0 |
BCAB Forecast & Estimates
9 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 1028.32% is expected in the next year compared to the current price of 0.904.
For the next year, analysts expect an EPS growth of 15.47% and a revenue growth -100% for BCAB